Medpace Holdings, Inc. (MEDP) EV/EBITDA Ratio: 21.40x
Is Medpace Holdings, Inc.’s EV/EBITDA ratio high or low?
Medpace Holdings, Inc.'s EV/EBITDA ratio of 21.40x is 16% below its 5-year average of 25.62x, near the low end of its 5-year range (16.49x–36.82x).
As of Wednesday, June 17, 2026. 17.75% below its 12-month average of 26.02x.
MEDP EV/EBITDA Ratio Chart
MEDP Average EV/EBITDA Ratio Chart
MEDP Current vs Average EV/EBITDA Ratio Chart
MEDP EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
21.40x
EV/EBITDA RATIO AVG TTM
26.02x
EV/EBITDA RATIO AVG 3Y
25.80x
EV/EBITDA RATIO AVG 5Y
25.62x
EV/EBITDA RATIO AVG 10Y
22.53x
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-17.75%
CURRENT VS 3Y AVG
-17.06%
CURRENT VS 5Y AVG
-16.48%
CURRENT VS 10Y AVG
-5.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.18B | 21.40x | 26.02x | 25.80x | 25.62x |
| The Cooper Companies, Inc. (COO)vs › | $13.22B | 17.94x | 15.97x | 20.12x | 21.91x |
| Solventum Corporation (SOLV)vs › | $13.26B | 6.52x | 10.06x | 10.27x | 10.27x |
| DaVita Inc. (DVA)vs › | $13.42B | 9.98x | 9.08x | 9.40x | 9.40x |
| Align Technology, Inc. (ALGN)vs › | $12.92B | 12.99x | 13.08x | 20.23x | 25.92x |
| Revvity, Inc. (RVTY)vs › | $11.29B | 17.88x | 17.08x | 19.86x | 18.22x |
| Baxter International Inc. (BAX)vs › | $10.57B | 24.67x | 20.35x | 19.14x | 19.12x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 21.34x | 19.40x | 19.09x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.28x | 15.01x | 15.35x | 12.41x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.99B | 41.61x | 24.57x | 17.42x | 18.50x |
EV/EBITDA vs. its own history
At 21.4, EV/EBITDA is in its normal range, sitting higher than 47% of its 10-year history.
10-year low
10.5
median
21.9
10-year high
38.3
Medpace Holdings, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Medpace Holdings, Inc. (MEDP)?
- The EV/EBITDA ratio for MEDP stock is 21.40x.
- Is Medpace Holdings, Inc.'s EV/EBITDA ratio high or low?
- Medpace Holdings, Inc.'s EV/EBITDA ratio of 21.40x is 16% below its 5-year average of 25.62x, near the low end of its 5-year range (16.49x–36.82x).
- What is the TTM average EV/EBITDA ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average EV/EBITDA ratio for MEDP stock is 26.02x.
- What is the 3Y average EV/EBITDA ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average EV/EBITDA ratio for MEDP stock is 25.80x.
- What is the 5Y average EV/EBITDA ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average EV/EBITDA ratio for MEDP stock is 25.62x.
- What is the 10Y average EV/EBITDA ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average EV/EBITDA ratio for MEDP stock is 22.53x.
Medpace Holdings, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-16 | 21.40x |
| 2026-06-15 | 21.69x |
| 2026-06-12 | 21.68x |
| 2026-06-11 | 22.05x |
| 2026-06-10 | 21.60x |
| 2026-06-09 | 21.65x |
| 2026-06-08 | 21.22x |
| 2026-06-05 | 21.05x |
| 2026-06-04 | 21.26x |
| 2026-06-03 | 20.88x |
| 2026-06-02 | 20.63x |
| 2026-06-01 | 20.91x |
| 2026-05-29 | 20.70x |
| 2026-05-28 | 20.75x |
| 2026-05-27 | 19.78x |
| 2026-05-26 | 19.83x |
| 2026-05-22 | 20.01x |
| 2026-05-21 | 19.88x |
| 2026-05-20 | 19.48x |
| 2026-05-19 | 19.39x |
| 2026-05-18 | 19.43x |
| 2026-05-15 | 19.16x |
| 2026-05-14 | 19.35x |
| 2026-05-13 | 19.57x |
| 2026-05-12 | 19.38x |
| 2026-05-11 | 19.26x |
| 2026-05-08 | 19.59x |
| 2026-05-07 | 19.81x |
| 2026-05-06 | 19.72x |
| 2026-05-05 | 19.89x |
| 2026-05-04 | 19.25x |
| 2026-05-01 | 19.27x |
| 2026-04-30 | 19.33x |
| 2026-04-29 | 19.08x |
| 2026-04-28 | 18.89x |
| 2026-04-27 | 19.46x |
| 2026-04-24 | 18.94x |
| 2026-04-23 | 18.11x |
| 2026-04-22 | 25.38x |
| 2026-04-21 | 25.71x |
| 2026-04-20 | 26.40x |
| 2026-04-17 | 26.00x |
| 2026-04-16 | 25.75x |
| 2026-04-15 | 25.89x |
| 2026-04-14 | 25.97x |
| 2026-04-13 | 25.01x |
| 2026-04-10 | 24.62x |
| 2026-04-09 | 25.03x |
| 2026-04-08 | 26.00x |
| 2026-04-07 | 25.39x |
| 2026-04-06 | 24.75x |
| 2026-04-02 | 24.87x |
| 2026-04-01 | 24.42x |
| 2026-03-31 | 23.95x |
| 2026-03-30 | 22.94x |
| 2026-03-27 | 22.47x |
| 2026-03-26 | 23.26x |
| 2026-03-25 | 23.27x |
| 2026-03-24 | 22.96x |
| 2026-03-23 | 22.77x |
| 2026-03-20 | 22.54x |
| 2026-03-19 | 22.97x |
| 2026-03-18 | 22.66x |
| 2026-03-17 | 22.68x |
| 2026-03-16 | 22.60x |
| 2026-03-13 | 22.43x |
| 2026-03-12 | 22.10x |
| 2026-03-11 | 23.82x |
| 2026-03-10 | 23.27x |
| 2026-03-09 | 23.86x |
| 2026-03-06 | 23.46x |
| 2026-03-05 | 23.40x |
| 2026-03-04 | 23.22x |
| 2026-03-03 | 23.19x |
| 2026-03-02 | 22.79x |
| 2026-02-27 | 22.50x |
| 2026-02-26 | 22.27x |
| 2026-02-25 | 21.81x |
| 2026-02-24 | 22.02x |
| 2026-02-23 | 22.16x |
| 2026-02-20 | 22.61x |
| 2026-02-19 | 22.23x |
| 2026-02-18 | 22.22x |
| 2026-02-17 | 21.31x |
| 2026-02-13 | 21.30x |
| 2026-02-12 | 20.69x |
| 2026-02-11 | 21.09x |
| 2026-02-10 | 22.21x |
| 2026-02-09 | 28.50x |
| 2026-02-06 | 29.13x |
| 2026-02-05 | 29.09x |
| 2026-02-04 | 30.19x |
| 2026-02-03 | 30.57x |
| 2026-02-02 | 31.63x |
| 2026-01-30 | 31.33x |
| 2026-01-29 | 31.90x |
| 2026-01-28 | 32.16x |
| 2026-01-27 | 32.40x |
| 2026-01-26 | 32.39x |
| 2026-01-23 | 31.63x |
| 2026-01-22 | 32.62x |
| 2026-01-21 | 33.39x |
| 2026-01-20 | 32.41x |
| 2026-01-16 | 32.87x |
| 2026-01-15 | 33.25x |
| 2026-01-14 | 33.17x |
| 2026-01-13 | 32.73x |
| 2026-01-12 | 32.23x |
| 2026-01-09 | 32.00x |
| 2026-01-08 | 32.28x |
| 2026-01-07 | 32.99x |
| 2026-01-06 | 32.76x |
| 2026-01-05 | 31.56x |
| 2026-01-02 | 30.70x |
| 2025-12-31 | 30.20x |
| 2025-12-30 | 30.59x |
| 2025-12-29 | 30.65x |
| 2025-12-26 | 30.52x |
| 2025-12-24 | 30.75x |
| 2025-12-23 | 30.63x |
| 2025-12-22 | 30.73x |
| 2025-12-19 | 30.56x |
| 2025-12-18 | 30.12x |
| 2025-12-17 | 29.95x |
| 2025-12-16 | 30.04x |
| 2025-12-15 | 30.06x |
| 2025-12-12 | 29.99x |
| 2025-12-11 | 30.44x |
| 2025-12-10 | 30.15x |
| 2025-12-09 | 29.24x |
| 2025-12-08 | 29.52x |
| 2025-12-05 | 29.46x |
| 2025-12-04 | 29.28x |
| 2025-12-03 | 31.00x |
| 2025-12-02 | 31.39x |
| 2025-12-01 | 31.62x |
| 2025-11-28 | 31.87x |
| 2025-11-26 | 32.63x |
| 2025-11-25 | 32.92x |
| 2025-11-24 | 33.28x |
| 2025-11-21 | 31.83x |
| 2025-11-20 | 31.53x |
| 2025-11-19 | 31.85x |
| 2025-11-18 | 31.74x |
| 2025-11-17 | 31.50x |
| 2025-11-14 | 31.74x |
| 2025-11-13 | 31.80x |
| 2025-11-12 | 32.15x |
| 2025-11-11 | 32.43x |
| 2025-11-10 | 32.30x |
| 2025-11-07 | 31.69x |
| 2025-11-06 | 31.85x |
| 2025-11-05 | 32.21x |
| 2025-11-04 | 31.98x |
| 2025-11-03 | 31.95x |
| 2025-10-31 | 31.46x |
| 2025-10-30 | 31.21x |
| 2025-10-29 | 31.44x |
| 2025-10-28 | 31.22x |
| 2025-10-27 | 32.08x |
| 2025-10-24 | 32.56x |
| 2025-10-23 | 32.09x |
| 2025-10-22 | 31.65x |
| 2025-10-21 | 31.59x |
| 2025-10-20 | 31.52x |
| 2025-10-17 | 30.58x |
| 2025-10-16 | 30.18x |
| 2025-10-15 | 29.79x |
| 2025-10-14 | 29.94x |
| 2025-10-13 | 30.54x |
| 2025-10-10 | 29.03x |
| 2025-10-09 | 30.04x |
| 2025-10-08 | 30.75x |
| 2025-10-07 | 30.79x |
| 2025-10-06 | 30.71x |
| 2025-10-03 | 30.83x |
| 2025-10-02 | 31.04x |
| 2025-10-01 | 31.49x |
| 2025-09-30 | 29.78x |
| 2025-09-29 | 29.01x |
| 2025-09-26 | 28.78x |
| 2025-09-25 | 28.27x |
| 2025-09-24 | 28.81x |
| 2025-09-23 | 28.74x |
| 2025-09-22 | 28.85x |
| 2025-09-19 | 28.88x |
| 2025-09-18 | 29.07x |
| 2025-09-17 | 28.84x |
| 2025-09-16 | 28.43x |
| 2025-09-15 | 28.76x |
| 2025-09-12 | 28.42x |
| 2025-09-11 | 28.82x |
| 2025-09-10 | 27.62x |
| 2025-09-09 | 28.13x |
| 2025-09-08 | 28.51x |
| 2025-09-05 | 28.21x |
| 2025-09-04 | 27.95x |
| 2025-09-03 | 27.88x |
| 2025-09-02 | 27.43x |
| 2025-08-29 | 27.55x |
| 2025-08-28 | 27.41x |
| 2025-08-27 | 27.44x |
| 2025-08-26 | 27.20x |
| 2025-08-25 | 27.05x |
| 2025-08-22 | 26.87x |
| 2025-08-21 | 26.28x |
| 2025-08-20 | 26.99x |
| 2025-08-19 | 26.78x |
| 2025-08-18 | 26.83x |
| 2025-08-15 | 26.54x |
| 2025-08-14 | 26.58x |
| 2025-08-13 | 27.12x |
| 2025-08-12 | 26.62x |
| 2025-08-11 | 26.07x |
| 2025-08-08 | 25.19x |
| 2025-08-07 | 24.87x |
| 2025-08-06 | 24.96x |
| 2025-08-05 | 25.30x |
| 2025-08-04 | 25.08x |
| 2025-08-01 | 24.54x |
| 2025-07-31 | 24.77x |
| 2025-07-30 | 25.38x |
| 2025-07-29 | 25.97x |
| 2025-07-28 | 26.26x |
| 2025-07-25 | 25.94x |
| 2025-07-24 | 26.41x |
| 2025-07-23 | 25.36x |
| 2025-07-22 | 27.68x |
| 2025-07-21 | 18.26x |
| 2025-07-18 | 18.44x |
| 2025-07-17 | 18.89x |
| 2025-07-16 | 18.62x |
| 2025-07-15 | 18.49x |
| 2025-07-14 | 18.96x |
| 2025-07-11 | 19.15x |
| 2025-07-10 | 19.44x |
| 2025-07-09 | 19.00x |
| 2025-07-08 | 19.09x |
| 2025-07-07 | 18.87x |
| 2025-07-03 | 19.03x |
| 2025-07-02 | 19.31x |
| 2025-07-01 | 19.00x |
| 2025-06-30 | 18.56x |
| 2025-06-27 | 18.37x |
| 2025-06-26 | 18.13x |
| 2025-06-25 | 18.40x |
| 2025-06-24 | 18.65x |
| 2025-06-23 | 18.24x |
| 2025-06-20 | 18.29x |
| 2025-06-18 | 17.88x |
| 2025-06-17 | 17.59x |
| 2025-06-16 | 17.78x |
| 2025-06-13 | 17.61x |
| 2025-06-12 | 17.96x |
| 2025-06-11 | 17.86x |
| 2025-06-10 | 18.08x |
| 2025-06-09 | 17.61x |
| 2025-06-06 | 17.50x |
| 2025-06-05 | 17.32x |
| 2025-06-04 | 18.49x |
Showing the most recent 260 of 2,475 data points. The chart above shows the full history.
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle